it's hard for me to believe genmab's drug would not have the same issues as ocrelizumab.
this is probably good news for biogen as Roche was getting a much higher stake in ocrelizumab than rituxan and would have cannibalized rituxan in RA sales.
i don't hold out much hope for the RRMS indication. the trial has been going on forever.
Market Data 
Markets 
AI
